Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation.
biomarkers
cellular
head and neck neoplasms
immunity
immunoassay
myeloid-derived suppressor cells
tumor
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
accepted:
24
07
2020
entrez:
10
9
2020
pubmed:
11
9
2020
medline:
15
10
2021
Statut:
ppublish
Résumé
Myeloid-derived suppressor cells (MDSC) are a functional myeloid cell subset that includes myeloid cells with immune suppressive properties. The presence of MDSC has been reported in the peripheral blood of patients with several malignant and non-malignant diseases. So far, direct comparison of MDSC across different diseases and Centers is hindered by technical pitfalls and a lack of standardized methodology. To overcome this issue, we formed a network through the COST Action Mye-EUNITER (www.mye-euniter.eu) with the goal to standardize and facilitate the comparative analysis of human circulating MDSC in cancer, inflammation and infection. In this manuscript, we present the results of the multicenter study Mye-EUNITER MDSC Monitoring Initiative, that involved 13 laboratories and compared circulating MDSC subsets across multiple diseases, using a common protocol for the isolation, identification and characterization of these cells. We developed, tested, executed and optimized a standard operating procedure for the isolation and immunophenotyping of MDSC using blood from healthy donors. We applied this procedure to the blood of almost 400 patients and controls with different solid tumors and non-malignant diseases. The latter included viral infections such as HIV and hepatitis B virus, but also psoriasis and cardiovascular disorders. We observed that the frequency of MDSC in healthy donors varied substantially between centers and was influenced by technical aspects such as the anticoagulant and separation method used. Expansion of polymorphonuclear (PMN)-MDSC exceeded the expansion of monocytic MDSC (M-MDSC) in five out of six solid tumors. PMN-MDSC expansion was more pronounced in cancer compared with infection and inflammation. Programmed death-ligand 1 was primarily expressed in M-MDSC and e-MDSC and was not upregulated as a consequence of disease. LOX-1 expression was confined to PMN-MDSC. This study provides improved technical protocols and workflows for the multi-center analysis of circulating human MDSC subsets. Application of these workflows revealed a predominant expansion of PMN-MDSC in solid tumors that exceeds expansion in chronic infection and inflammation.
Sections du résumé
BACKGROUND
Myeloid-derived suppressor cells (MDSC) are a functional myeloid cell subset that includes myeloid cells with immune suppressive properties. The presence of MDSC has been reported in the peripheral blood of patients with several malignant and non-malignant diseases. So far, direct comparison of MDSC across different diseases and Centers is hindered by technical pitfalls and a lack of standardized methodology. To overcome this issue, we formed a network through the COST Action Mye-EUNITER (www.mye-euniter.eu) with the goal to standardize and facilitate the comparative analysis of human circulating MDSC in cancer, inflammation and infection. In this manuscript, we present the results of the multicenter study Mye-EUNITER MDSC Monitoring Initiative, that involved 13 laboratories and compared circulating MDSC subsets across multiple diseases, using a common protocol for the isolation, identification and characterization of these cells.
METHODS
We developed, tested, executed and optimized a standard operating procedure for the isolation and immunophenotyping of MDSC using blood from healthy donors. We applied this procedure to the blood of almost 400 patients and controls with different solid tumors and non-malignant diseases. The latter included viral infections such as HIV and hepatitis B virus, but also psoriasis and cardiovascular disorders.
RESULTS
We observed that the frequency of MDSC in healthy donors varied substantially between centers and was influenced by technical aspects such as the anticoagulant and separation method used. Expansion of polymorphonuclear (PMN)-MDSC exceeded the expansion of monocytic MDSC (M-MDSC) in five out of six solid tumors. PMN-MDSC expansion was more pronounced in cancer compared with infection and inflammation. Programmed death-ligand 1 was primarily expressed in M-MDSC and e-MDSC and was not upregulated as a consequence of disease. LOX-1 expression was confined to PMN-MDSC.
CONCLUSIONS
This study provides improved technical protocols and workflows for the multi-center analysis of circulating human MDSC subsets. Application of these workflows revealed a predominant expansion of PMN-MDSC in solid tumors that exceeds expansion in chronic infection and inflammation.
Identifiants
pubmed: 32907925
pii: jitc-2020-001223
doi: 10.1136/jitc-2020-001223
pmc: PMC7481096
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Medical Research Council
ID : G1002033
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N022556/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N022556/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 101067/Z/13/Z
Pays : United Kingdom
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Cancer Immunol Immunother. 2019 Apr;68(4):687-697
pubmed: 30684003
Sci Immunol. 2019 Oct 18;4(40):
pubmed: 31628161
Hum Immunol. 2014 Nov;75(11):1128-37
pubmed: 25305034
Nat Rev Immunol. 2009 Mar;9(3):162-74
pubmed: 19197294
Front Immunol. 2018 Mar 02;9:398
pubmed: 29552012
J Acquir Immune Defic Syndr. 2017 Oct 1;76(2):200-208
pubmed: 28570288
Front Immunol. 2019 Aug 27;10:2022
pubmed: 31507611
Aliment Pharmacol Ther. 2019 May;49(10):1346-1359
pubmed: 30982998
Cancer Immunol Res. 2017 Jan;5(1):3-8
pubmed: 28052991
Nat Rev Cancer. 2013 Oct;13(10):739-52
pubmed: 24060865
J Immunol. 2018 Jan 1;200(1):286-294
pubmed: 29180488
Front Immunol. 2018 Jun 11;9:1310
pubmed: 29942309
Nat Immunol. 2018 Feb;19(2):108-119
pubmed: 29348500
Nat Commun. 2016 Jul 06;7:12150
pubmed: 27381735
Front Immunol. 2019 Jul 23;10:1715
pubmed: 31396227
Clin Cancer Res. 2018 Oct 1;24(19):4834-4844
pubmed: 29914893
Cancer Immunol Immunother. 2016 Feb;65(2):161-9
pubmed: 26728481
Mol Med Rep. 2016 Oct;14(4):3935-40
pubmed: 27574042
J Immunother Cancer. 2019 Aug 28;7(1):230
pubmed: 31462270
JCI Insight. 2018 Mar 22;3(6):
pubmed: 29563330
Eur J Immunol. 2009 Oct;39(10):2865-76
pubmed: 19637228
Cancer Immunol Immunother. 2019 Apr;68(4):645-660
pubmed: 30003321
J Invest Dermatol. 2020 Jul;140(7):1371-1378.e3
pubmed: 31945345
Breast Cancer Res Treat. 2013 Jul;140(1):13-21
pubmed: 23828498
Cent Eur J Immunol. 2017;42(4):383-389
pubmed: 29472817
Circulation. 2018 Jul 10;138(2):181-197
pubmed: 29437117
Sci Immunol. 2016 Aug;1(2):
pubmed: 28417112
Cancer Res. 2007 Jan 1;67(1):425; author reply 426
pubmed: 17210725
Trends Pharmacol Sci. 2019 Jan;40(1):4-7
pubmed: 30527590